CRISPR is the sharpest tool I’ve worked with in genetic medicine, and its ability to cut out inherited mutations at the source is unlike anything we’ve had before. I’ve watched it move from Petri dishes to patients—people with sickle cell disease and beta-thalassemia living without symptoms after a single edited treatment. It’s tempting to think this could end genetic disease entirely, but the truth is more complicated. Editing a gene isn’t the same as delivering a cure to every person who needs it. There are technical challenges, safety limits, and delivery barriers still in play. What I can say with certainty is this: CRISPR is reshaping medicine, and if we keep refining it, it may erase entire categories of inherited illness from the future.
Editing Genes at the Molecular Level
When I apply CRISPR-Cas9 in a research setting, I’m targeting precise locations in the DNA—spots we’ve sequenced and mapped to a known mutation. Using a guide RNA and an enzyme like Cas9, we make a clean cut at the defect site. Sometimes we just knock the gene out. Other times, we insert a corrected version. What matters is the precision—we’re not hoping for improvement; we’re rewriting the code.
This level of control wasn’t possible with older techniques. CRISPR is faster to design, easier to scale, and cheaper to execute. That’s why labs like mine—and many others—have moved quickly from testing in cell lines to applying it in patient-derived cells and, in some trials, directly into living tissue.
Results That Go Beyond the Lab
When I followed the initial sickle cell disease trials, I was stunned by how effective the edits were. Patients went from needing monthly blood transfusions to complete independence. The CRISPR edit was done on their stem cells outside the body. Once those cells were reinfused, they began producing normal hemoglobin.
The first time I saw those data points translate into a person’s life without crisis episodes, it shifted my outlook. We’re not managing disease anymore—we’re reversing it. In one case of Leber congenital amaurosis, CRISPR was injected directly into the eye. The patient began to regain sight. That wasn’t just a proof of concept. It was a real, functional recovery from a genetic condition once thought untreatable.
Delivery Is Still a Bottleneck
Every time I’ve tried to deliver CRISPR components in vivo, I’ve had to make trade-offs. We can’t just sprinkle gene editors into the bloodstream and hope they find their target. I’ve worked with viral vectors, lipid nanoparticles, and electroporation—all of them have strengths and downsides.
AAV vectors are efficient but limited by payload size. They also trigger immune responses in some patients. Lipid nanoparticles are promising and easier to program, but they tend to cluster in the liver unless specifically modified. For now, I use ex vivo editing where possible—it gives me more control. But long-term, we need a universal delivery platform that can reach multiple tissue types safely.
Safety Means Knowing Where Else You’re Editing
CRISPR is accurate, but not flawless. I run whole-genome sequencing after every edit to check for off-target effects—those accidental cuts that might disrupt healthy genes or activate harmful ones. Even when edits look successful, I keep monitoring the cells through several passages to make sure nothing changes downstream.
We’ve made progress with high-fidelity Cas9 variants, and I now use these to reduce off-target risk. But in human applications, especially in vivo, I don’t trust any tool until I’ve validated it in a complete preclinical model. One misstep in editing can undo all the good we’re trying to do.
Germline Editing Is a Red Line—for Now
Germline editing is where the ethical and technical stakes spike. I’ve had conversations with colleagues about correcting mutations at the embryo level, and while the idea is tempting for single-gene diseases, we’re not there yet. The science is young, and the risks are permanent.
Every time I speak on this topic, I remind people: somatic cell edits affect one patient. Germline edits affect generations. That means we need more than good intentions—we need regulation, transparency, and oversight. Until we can guarantee complete accuracy and societal consensus, germline edits stay in the realm of research only.
Not Every Condition Can Be Edited—Yet
CRISPR isn’t a catch-all. I can fix monogenic diseases where the mutation is well-defined. But I can’t apply the same method to conditions like autism, epilepsy, or schizophrenia. Those involve hundreds of genes and environmental triggers. We’d need multi-site editing, better phenotyping, and more predictive genomics before that becomes viable.
Even in monogenic cases, timing matters. Some diseases cause irreversible damage during fetal development. If we don’t catch them early, editing won’t reverse structural loss. That’s why I’m investing time in newborn screening integrations. The earlier I identify the mutation, the more effective the correction can be.
Affordability Is the Next Scientific Barrier
CRISPR isn’t cheap yet. The process of harvesting, editing, and reinfusing stem cells requires high-end equipment, GMP facilities, and trained specialists. I’ve worked on ways to reduce the complexity, but we still need to bring the cost down if this is going to be available to every patient who needs it.
Some of the most exciting work I’ve seen is moving toward “one-and-done” in vivo injections. These therapies deliver CRISPR directly to the affected tissue without removing any cells. They’re faster, cheaper, and easier to scale. That’s how we turn CRISPR from a research tool into a global therapy.
The Tools Are Getting Better
Base editing and prime editing are the upgrades I’m currently using in the lab. They allow single-letter DNA changes without cutting both strands. That dramatically reduces the risk of off-target errors and improves the safety profile for in vivo applications. I’ve used base editors on patient-derived cells with success in correcting point mutations linked to inherited liver disorders.
What I’m most excited about next is multiplex editing—fixing multiple mutations at once. For complex diseases or cases where a single edit isn’t enough, this gives us a way to intervene more comprehensively. The future of gene editing won’t rely on one enzyme or one approach. It’ll be a toolkit, customized to each disease—and each patient.
What CRISPR Is Doing Now
- Gene edits have cured sickle cell and beta-thalassemia in trials
- First in-body CRISPR treatments have restored vision
- Tools now include base and prime editors
- Off-target effects and delivery methods are still being refined
In Conclusion
CRISPR isn’t a theory—it’s a working tool I use to rewrite disease-causing mutations. It won’t erase every genetic disease today, but it’s already delivering cures in clinical trials. As we improve delivery, minimize risk, and expand access, CRISPR moves from revolutionary to routine. With the right application and continued progress, it may not just treat genetic disorders—it may make them history.
Can CRISPR truly eliminate inherited diseases? In this deep dive, Nirdosh Jagota explores how gene editing is transforming from a high-tech lab tool into a real-world therapy—reversing sickle cell, restoring vision, and rewriting the future of medicine.
Nirdosh Jagota is Managing Partner at GRQ Biotech Advisors with 30+ years in the biotech industry. A former executive at Amgen, Genentech/Roche, Merck, and Pfizer, he has led >25 NDAs/BLAs/MAAs and hundreds of INDs across global regulatory, quality, and compliance.